Skip to main content

Ming Chen

Associate Professor of Pathology
Pathology
Duke Box 103863, Durham, NC 27710
905 S LaSalle St, GSRB1, Rm 2014, Durham, NC 27710

Overview


Our laboratory is interested in understanding the molecular and genetic events underlying cancer progression and metastasis. The focus of our work is a series of genetically engineered mouse models that faithfully recapitulate human disease. Using a combination of mouse genetics, omics technologies, cross-species analyses and in vitro approaches, we aim to identify cancer cell–intrinsic and –extrinsic mechanisms driving metastatic cancer progression, with a long–term goal of developing new therapeutic strategies for preventing and treating metastatic disease. 

Current Appointments & Affiliations


Associate Professor of Pathology · 2022 - Present Pathology, Clinical Science Departments
Associate Research Professor of Cell Biology · 2022 - Present Cell Biology, Basic Science Departments
Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published December 3, 2024
Research & Innovation Seed Grants Total Nearly $2 Million
Published May 17, 2023
Duke Scientists Uncover Ferroptosis as a Potential “Achilles Heel” in RB1-Deficient Prostate Cancer
Published April 26, 2018
Prostate Cancer Metastasis — Fueled by Fat?

View All News

Recent Publications


Comparative analysis of gene regulation in single cells using Compass.

Journal Article Cell Rep Methods · April 30, 2025 Single-cell multi-omics is a transformative technology that measures both gene expression and chromatin accessibility in individual cells. However, most studies concentrate on a single tissue and are unable to determine whether a gene is regulated by a cis ... Full text Open Access Link to item Cite

Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.

Journal Article Vaccines (Basel) · November 13, 2024 Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target thi ... Full text Link to item Cite

IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.

Journal Article J Exp Med · November 4, 2024 Acquisition of prostate cancer stem cells (PCSCs) manifested during androgen ablation therapy (ABT) contributes to castration-resistant prostate cancer (CRPC). However, little is known about the specific metabolites critically orchestrating this process. H ... Full text Link to item Cite
View All Publications

Recent Grants


Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027

Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027

Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology for Prostate Cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027

View All Grants

Education, Training & Certifications


University of Rochester · 2009 Ph.D.